You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Temelimab

Showing 1 - 12 of 12
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Multiple Sclerosis Trial in Stockholm (temelimab 18 mg/kg, temelimab 36 mg/kg, temelimab 54 mg/kg)

Completed
  • Multiple Sclerosis
  • temelimab 18 mg/kg
  • +3 more
  • Stockholm, Sweden
    Center for Neurology, Academic Specialist Center
Jul 4, 2022

Multiple Sclerosis Trial in Stockholm (Temelimab 18 mg/kg, Temelimab 36mg/kg, Temelimab 54 mg/kg)

Terminated
  • Multiple Sclerosis
  • Temelimab 18 mg/kg
  • +2 more
  • Stockholm, Sweden
    Center for Neurology, Academic Specialist Center
Jul 4, 2022

Post-COVID-19 Syndrome Trial in Geneva (Temelimab 54mg/kg, Placebo)

Not yet recruiting
  • Post-COVID-19 Syndrome
  • Temelimab 54mg/kg
  • Placebo
  • Geneva, Switzerland
    Geneva University Hospital
Aug 9, 2022

Multiple Sclerosis Trial in Basel, Geneva (GNbAC1, GNbAC1 )

Completed
  • Multiple Sclerosis
  • GNbAC1
  • GNbAC1 placebo
  • Basel, Switzerland
  • +1 more
Feb 5, 2021

MSRV-Env Burden in Normal Population

Completed
  • Multiple Sclerosis
  • No study treatments administered
  • Annemasse, France
    Etablissement Français du Sang Rhône Alpes - 1 route de Taninges
Oct 19, 2020

Multiple Sclerosis Trial in Sydney (GNbAC1, GNbAC1 Placebo)

Completed
  • Multiple Sclerosis
  • Sydney, New South Wales, Australia
    Scientia Clinical Research Ltd
Oct 19, 2020

Multiple Sclerosis, Relapsing-Remitting Trial in Worldwide (GNbAC1, Placebo)

Completed
  • Multiple Sclerosis, Relapsing-Remitting
  • Sofia, Bulgaria
  • +11 more
Oct 19, 2020

Multiple Sclerosis, Relapsing-Remitting Trial in Worldwide (GNbAC1 Monoclonal Antibody)

Terminated
  • Multiple Sclerosis, Relapsing-Remitting
  • GNbAC1 Monoclonal Antibody
  • Sofia, Bulgaria
  • +11 more
Oct 19, 2020

Healthy Volunteers Trial in Berlin (GNbAC1)

Completed
  • Healthy Volunteers
  • Berlin, Germany
    PAREXEL Early Phase Clinical Unit
Oct 19, 2020

Diabetes Type 1 Trial in Australia (GNbAC1, Placebo)

Completed
  • Diabetes Mellitus Type 1
  • Macquarie University, New South Wales, Australia
  • +12 more
Oct 19, 2020

MSRV-Env Burden in Patients With Multiple Sclerosis Disease

Completed
  • Multiple Sclerosis (MS)
  • +4 more
  • No study treatments administered - blood draws only
  • Bron cedex, France
  • +3 more
Oct 19, 2020

Multiple Sclerosis Trial (GNbAC1, GNbAC1 )

Completed
  • Multiple Sclerosis
  • GNbAC1
  • GNbAC1 placebo
  • (no location specified)
Oct 19, 2020